How Much Does An Iron Infusion Cost?

Updated on August 30, 2026 | Written by Alec Pow
This article was researched using 14 sources. See our methodology and corrections policy.

An iron infusion can cost from a few hundred dollars to $3,000 or more before insurance, depending heavily on the IV iron prescribed, dose, number of visits, and treatment location. Current U.S. hospital price-transparency data show a median published cash price of about $134 for an iron sucrose drug line, while the median published cash price for an Injectafer drug line is about $1,933. These figures are hospital-published drug prices, not guaranteed all-inclusive infusion bills.

The full course matters more than the price of one appointment. Some IV iron products can deliver the prescribed replacement dose in one visit, others commonly require two visits, and one Venofer regimen uses five administrations. Facility, infusion-administration, office, laboratory, and insurance charges can therefore make a lower-priced drug more expensive to receive over several visits.

There is no trustworthy national out-of-pocket average for every patient. Someone with strong insurance coverage may owe a relatively small copay or coinsurance amount, while a cash-paying patient can face thousands of dollars. The useful comparison is the estimated cost of the entire prescribed treatment course, not just the price advertised for one infusion.

Article Highlights

• Current U.S. medication and hospital cash-price benchmarks range from roughly hundreds to several thousand dollars, depending on the IV iron product and dose.
• One common Venofer regimen uses five 200 mg administrations to deliver 1,000 mg, while Monoferric can deliver 1,000 mg in one infusion for patients weighing at least 50 kg.
• Feraheme is normally given as two 510 mg doses, 3 to 8 days apart.
• Injectafer can use two 750 mg doses separated by at least seven days for patients weighing 50 kg or more, with an alternative single-dose regimen available for certain adults.
• Medicare Part B patients commonly pay up to 20% of the Medicare-approved amount for covered Part B drugs after the deductible, although hospital outpatient charges and other coverage can change the final responsibility.
• The treatment site, drug selected, number of appointments, laboratory monitoring, deductible, coinsurance, and authorization rules can matter more than the IV supplies themselves.

How Much Does an Iron Infusion Cost?

IV iron example	Typical course pattern	Current medication-only cash benchmark
Venofer, iron sucrose	200 mg × 5 visits = 1,000 mg for one labeled non-dialysis CKD regimen	A 50 mL package containing five 10 mL, 200 mg vials is currently listed around $359.55 to $642.33.
Generic ferumoxytol	510 mg × 2 visits = 1,020 mg	A 510 mg vial is currently listed around $768.29, making two vials about $1,536.58 (at $30 per hour, earning that amount would take about 1.3 full-time workweeks, before taxes).
Injectafer	750 mg × 2 visits = 1,500 mg for a common adult course	A 750 mg vial is currently listed around $1,742.44, or about $3,484.88 for two at that cash benchmark.
Monoferric	1,000 mg × 1 visit for patients weighing at least 50 kg	The 1,000 mg vial is currently listed around $3,718.05.

These are medication-price benchmarks, not quotes for treatment. Infusion centers do not necessarily buy the drugs at these retail cash prices, insurers negotiate different allowed amounts, and a patient’s bill can add administration and facility services. The drug table is useful for showing why IV iron prices differ so sharply before insurance and site-of-care differences enter the calculation.

One Dose vs. Five Visits

The number of appointments is one of the hidden price drivers. Current Venofer dosing instructions include a non-dialysis-dependent chronic kidney disease regimen of 200 mg on five occasions over 14 days. That supplies a cumulative 1,000 mg of iron.

Monoferric takes a different approach. Its current FDA-approved dosing allows patients weighing 50 kg or more to receive 1,000 mg in one infusion lasting at least 20 minutes. Patients weighing less than 50 kg receive weight-based dosing.

Feraheme sits between those schedules. The FDA’s May 2026 current Feraheme label specifies an initial 510 mg infusion followed by another 510 mg infusion 3 to 8 days later.

The drug requiring the fewest visits is not automatically the cheapest choice. The physician selects a formulation and regimen based on the patient’s clinical circumstances, product indications, risks, coverage, and other considerations. The cost lesson is that comparing only one vial price leaves out the number of times the patient must return.

ThePricer Full-Course Math

The current cash medication benchmarks make the visit tradeoff visible. Five 10 mL Venofer vials contain a total of 1,000 mg and are currently listed at about $359.55 to $642.33 (about 1.5 to 2.7 full-time workdays at $30 per hour) for the package. Monoferric supplies 1,000 mg in a single vial currently listed around $3,718.05.

The medication-only difference is therefore $3,075.72 to $3,358.50. In exchange, the labeled examples above involve one Monoferric administration instead of five Venofer administrations. That is four fewer infusion visits. It does not prove one treatment is financially or medically preferable because provider prices, indications, insurance contracts, and administration charges can reverse the comparison.

Ferumoxytol creates another useful middle case. Two current generic 510 mg vials at $768.29 each calculate to $1,536.58 for 1,020 mg. That is about $2,181.47 less than the listed $3,718.05 Monoferric medication price, while requiring two administrations rather than one.

Injectafer has also changed as a pricing comparison because generic ferric carboxymaltose entered the U.S. market in 2026. Current generic pricing lists a 750 mg vial at about $1,286.33 to $1,341.47. Two 750 mg vials calculate to $2,572.66 to $2,682.94. Against two branded Injectafer vials at about $3,484.88, the medication-only difference is approximately $801.94 to $912.22 per 1,500 mg course.

That generic-versus-brand calculation is a drug-price comparison only. A patient should ask whether the specific generic is covered, available at the treatment site, and appropriate for the prescribed order rather than assuming the lower listed medication price will automatically appear on the final claim.

What Insurance Changes

Insurance can turn a multi-thousand-dollar billed treatment into a much smaller patient responsibility, but “covered” does not mean free. The important questions are whether the product is covered under the medical benefit, whether prior authorization or step requirements apply, which infusion sites are in network, and how much of the deductible remains.

For Original Medicare, Medicare’s current Part B drug guidance says patients generally pay up to 20% of the Medicare-approved amount for covered Part B drugs after meeting the Part B deductible. Certain drugs may carry lower coinsurance because of Medicare’s inflation-rebate rules.

The location can add another layer. Medicare notes that covered treatment in a hospital outpatient department may carry a separate hospital copayment in addition to applicable doctor or drug cost sharing. Supplemental coverage, Medicare Advantage, Medicaid, employer insurance, or another secondary plan can change what the patient actually owes.

Commercial plans can prefer one IV iron product over another or direct treatment to a particular infusion center. Before treatment, ask the insurer or infusion provider for the expected allowed amount, deductible remaining, coinsurance, prior-authorization status, and estimated patient responsibility for the whole course.

Manufacturer assistance may reduce eligible commercial-insurance costs for particular products. For example, the current Injectafer Savings Program says eligible commercially insured patients may pay as little as $50 (about 1.7 hours of work at $30 per hour) per dose, subject to its eligibility rules and savings limits. Cash-paying and government-insured patients do not qualify for that specific copay program.

The Hidden Facility Bill

The medication is only one possible claim line. An infusion appointment can also generate charges for IV administration, the treatment facility, clinician services, supplies, and laboratory testing. A hospital outpatient department and a physician-office or independent infusion setting can therefore produce different totals even when the same drug and dose are used.

The size of that spread is visible in hospital price-transparency files. Current data compiled from U.S. hospital files show a median published cash price of about $1,933 for the Injectafer drug line across more than 1,300 hospitals publishing a cash price. The middle portion of those hospitals spans roughly $310 to $2,900.

Those published prices are not the amount every patient will owe. They do show why a national “iron infusion costs $X” answer is misleading. Two patients receiving the same medication can encounter very different hospital cash prices and insurer-negotiated rates before their own deductible and coinsurance are applied.

Ask for an estimate using the exact drug name, dose, number of planned administrations, administration code, and treatment location. A quote covering only the medication is incomplete if the facility will bill other services separately.

When IV Iron Is Used

IV iron is not simply a premium version of an iron tablet. The American Gastroenterological Association’s current iron-deficiency anemia guidance recommends IV iron when oral iron is not tolerated, iron stores do not improve with an oral trial, or the patient has a condition in which oral iron is unlikely to be absorbed.

The same guidance prefers IV iron formulations that can replace the iron deficit in one or two infusions rather than products requiring more than two when an appropriate choice is available. That recommendation helps explain why visit count belongs in a cost comparison.

The underlying cause still matters. Iron deficiency can result from blood loss, gastrointestinal disease, malabsorption, bariatric procedures, pregnancy, chronic kidney disease, inflammatory conditions, and other causes. Replacing iron does not eliminate the need to evaluate and manage the reason iron became depleted when clinically appropriate.

The response also should not be priced around a promise that someone will “feel better in one or two days.” Symptom and laboratory responses vary. Follow-up timing is determined by the treating clinician and the patient’s condition rather than a universal immediate-response schedule.

Safety Changes the Setting

IV iron is administered in a setting equipped to recognize and treat infusion reactions. Product labels include specific observation instructions. Monoferric requires monitoring for signs and symptoms of hypersensitivity during and for at least 30 minutes after the infusion. Feraheme carries a boxed warning for serious hypersensitivity and anaphylaxis and also requires observation for at least 30 minutes after administration.

Injectafer has product-specific precautions as well. The current FDA Injectafer label calls for hypersensitivity monitoring and identifies symptomatic hypophosphatemia as a warning, with serum phosphate monitoring recommended for certain at-risk patients receiving repeat treatment.

The old idea that IV iron skin staining is temporary is also unsafe to repeat. Injectafer labeling warns that leakage outside the vein can produce long-lasting brown discoloration at the extravasation site. Pain, burning, swelling, or another unusual sensation around the IV should be reported to the infusion staff immediately.

Iron overload is another reason treatment is based on laboratory and clinical evaluation rather than simply buying additional doses. IV iron labels call for monitoring hematologic response and avoiding administration to patients with iron overload.

When Cost Questions Matter Most

Makes sense to request a detailed estimate if:

• Your deductible has not been met and the infusion is scheduled soon.
• Your insurer lists several IV iron products with different preferred or authorization status.
• You have a choice between a hospital outpatient department and another in-network infusion site.
• The prescribed course involves several visits and you want to know whether each visit generates another administration or facility charge.
• You are uninsured or paying cash and need the self-pay price for the drug plus administration.

Do not compare prices without checking:

• The exact drug and total milligrams prescribed.
• Whether the quoted price is per vial, per dose, per visit, or for the complete course.
• Whether administration and facility charges are included.
• Whether laboratory testing is billed separately.
• Whether the facility and ordering clinician are both in network.
• Whether manufacturer assistance applies to your insurance type.

What We Checked

• Checked current FDA dosing and safety information for major IV iron formulations rather than relying on older insurer claims or discontinued products.
• Confirmed that current AGA guidance favors formulations capable of replacing an iron deficit in one or two infusions when appropriate.
• Cross-referenced 2026 hospital price-transparency data with current medication cash-price guides to separate published drug pricing from the complete infusion bill.
• Verified Medicare’s current Part B explanation rather than assuming every patient receives automatic 80% coverage under one universal iron-infusion rule.

Related medical expenses can also appear before or after treatment. Iron deficiency is commonly tracked with laboratory testing, so our guide to blood test costs provides a separate benchmark. Depending on why anemia is being investigated, patients may also encounter biopsy costs or other diagnostic procedures. For another example of a treatment where the medication and administration setting both affect the final bill, see our breakdown of epidural injection costs.

Answers to Common Questions

How much does one iron infusion cost without insurance?
There is no single cash price. Current medication and hospital-published price benchmarks run from the low hundreds to several thousand dollars depending on the drug, dose, facility, and whether administration charges are included. Ask for a self-pay estimate for the exact prescribed drug and dose.

Why are some iron infusions much more expensive?
The medication itself can differ by thousands of dollars, and some products require more appointments than others. Facility prices, administration charges, insurance contracts, and the total dose also change the bill.

How many iron infusions will I need?
It depends on the product and prescribed regimen. Examples include one 1,000 mg Monoferric infusion, two 510 mg Feraheme infusions, or five 200 mg Venofer administrations for one labeled non-dialysis CKD regimen. Your clinician determines the appropriate treatment.

Does Medicare pay for iron infusions?
Medicare Part B can cover medically necessary physician-administered drugs when coverage requirements are met. After the deductible, the patient generally pays up to 20% of the Medicare-approved amount for covered Part B drugs, although other coverage and hospital outpatient charges can change the final responsibility.

Can an iron infusion leave a permanent stain?
Iron leaking outside the vein can cause brown skin discoloration that may be long lasting. Tell the infusion staff immediately about pain, burning, swelling, or another unusual sensation at the IV site.

How quickly does an iron infusion work?
Response varies with the severity and cause of the iron deficiency, the product used, and the individual patient. Laboratory and symptom improvement should be assessed on the schedule recommended by the treating clinician rather than assuming a fixed one- or two-day response.